BMRN vs. KNSA
Compare and contrast key facts about BioMarin Pharmaceutical Inc. (BMRN) and Kiniksa Pharmaceuticals, Ltd. (KNSA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BMRN or KNSA.
Correlation
The correlation between BMRN and KNSA is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BMRN vs. KNSA - Performance Comparison
Loading data...
Key characteristics
BMRN:
-0.66
KNSA:
0.60
BMRN:
-0.81
KNSA:
1.39
BMRN:
0.87
KNSA:
1.18
BMRN:
-0.41
KNSA:
0.83
BMRN:
-1.04
KNSA:
1.94
BMRN:
24.50%
KNSA:
17.92%
BMRN:
35.13%
KNSA:
50.85%
BMRN:
-90.58%
KNSA:
-83.06%
BMRN:
-60.26%
KNSA:
-15.13%
Fundamentals
BMRN:
$11.37B
KNSA:
$1.92B
BMRN:
$2.70
KNSA:
-$0.24
BMRN:
3.85
KNSA:
3.98
BMRN:
1.93
KNSA:
4.12
BMRN:
$2.94B
KNSA:
$481.17M
BMRN:
$2.32B
KNSA:
$389.86M
BMRN:
$738.30M
KNSA:
-$14.97M
Returns By Period
In the year-to-date period, BMRN achieves a -9.83% return, which is significantly lower than KNSA's 32.71% return.
BMRN
-9.83%
0.17%
-6.54%
-23.58%
-9.10%
-7.43%
KNSA
32.71%
29.89%
23.30%
32.78%
4.11%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BMRN vs. KNSA — Risk-Adjusted Performance Rank
BMRN
KNSA
BMRN vs. KNSA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
BMRN vs. KNSA - Dividend Comparison
Neither BMRN nor KNSA has paid dividends to shareholders.
Drawdowns
BMRN vs. KNSA - Drawdown Comparison
The maximum BMRN drawdown since its inception was -90.58%, which is greater than KNSA's maximum drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for BMRN and KNSA. For additional features, visit the drawdowns tool.
Loading data...
Volatility
BMRN vs. KNSA - Volatility Comparison
The current volatility for BioMarin Pharmaceutical Inc. (BMRN) is 9.26%, while Kiniksa Pharmaceuticals, Ltd. (KNSA) has a volatility of 21.75%. This indicates that BMRN experiences smaller price fluctuations and is considered to be less risky than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
BMRN vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between BioMarin Pharmaceutical Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMRN vs. KNSA - Profitability Comparison
BMRN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported a gross profit of 593.59M and revenue of 745.15M. Therefore, the gross margin over that period was 79.7%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 76.13M and revenue of 137.79M. Therefore, the gross margin over that period was 55.3%.
BMRN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported an operating income of 223.89M and revenue of 745.15M, resulting in an operating margin of 30.1%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 13.27M and revenue of 137.79M, resulting in an operating margin of 9.6%.
BMRN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported a net income of 185.69M and revenue of 745.15M, resulting in a net margin of 24.9%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Kiniksa Pharmaceuticals, Ltd. reported a net income of 8.54M and revenue of 137.79M, resulting in a net margin of 6.2%.